Key terms
About ARGX
argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ARGX news
Today
5:50am ET
Analysts’ Top Healthcare Picks: Elevance Health (ELV), Argenx Se (ARGX)
Yesterday
12:25pm ET
Maintaining the Edge: Argenx’s Hold Rating Amidst Rising Competition and Promising Therapy Results
Yesterday
6:30am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
Apr 16
6:58am ET
Argenx’s VYVGART Shows Promising CIDP Treatment Results
Apr 16
5:33am ET
Argenx presents data from ADHERE trial evaluating Vyvgart Hytrulo
Apr 15
7:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Argenx Se (ARGX), Neogen (NEOG) and Supernus Pharmaceuticals (SUPN)
Apr 12
9:36am ET
Argenx Se (ARGX) Receives a Buy from Bank of America Securities
Apr 03
4:15am ET
UBS Reaffirms Their Hold Rating on Argenx Se (ARGX)
Mar 29
3:09am ET
Buy Rating Affirmed for Argenx Se on Efgartigimod Progress and Regulatory Success
Mar 28
5:10am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 28
5:01am ET
Analysts Offer Insights on Healthcare Companies: Moderna (MRNA), Argenx Se (ARGX) and NovoCure (NVCR)
Mar 27
4:07pm ET
Immunovant initiated with an Outperform at Oppenheimer
Mar 27
5:21am ET
Argenx advances clinical development of efgartigimod
Mar 26
12:35pm ET
Reaffirming Buy Rating for Argenx with New Price Objective Following Vyvgart’s Approval in Japan
Mar 26
7:10am ET
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), BioMarin Pharmaceutical (BMRN) and Argenx Se (ARGX)
Mar 26
7:01am ET
Argenx’s VYVGART Wins Approval in Japan for ITP
Mar 24
9:45pm ET
Buy Rating Affirmed for Argenx Following Competitive Drug Trial Failure and Promising Market Prospects for Vyvgart
Mar 22
5:18am ET
Wells Fargo Issues a Buy Rating on Argenx Se (ARGX)
Mar 21
3:45pm ET
Buy Rating for Argenx Se Amid VYVGART’s Market Dominance and Revenue Growth Forecast
Mar 21
10:54am ET
Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
Mar 21
10:54am ET
Rocheâs mixed myasthenia gravis data sending these stocks in opposite directions
Mar 21
8:12am ET
Immunovant rallies after Chugai myasthenia gravis study failure
Mar 21
7:15am ET
Argenx rallies after Chugai generalized myasthenia gravis study fails
Mar 21
6:59am ET
Argenx Highlights 2023 Achievements and Outlook
Mar 15
2:54pm ET
Argenx price target raised to EUR 477 from EUR 465 at Morgan Stanley
Mar 06
7:37am ET
TD Cowen Sticks to Their Buy Rating for Argenx Se (ARGX)
Mar 05
2:55pm ET
Argenx price target lowered to EUR 490 from EUR 510 at JPMorgan
Mar 05
7:31am ET
Analysts Are Bullish on Top Healthcare Stocks: Arcellx Inc (ACLX), Astria Therapeutics (ATXS)
Mar 05
7:13am ET
Argenx price target raised to $440 from $370 at Truist
Mar 01
7:50am ET
Argenx price target raised to $440 from $430 at Guggenheim
Mar 01
7:08am ET
Argenx price target raised to $402 from $346 at Scotiabank
No recent press releases are available for ARGX
ARGX Financials
Key terms
Ad Feedback
ARGX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ARGX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
